PMID- 31313842
OWN - NLM
STAT- MEDLINE
DCOM- 20201013
LR  - 20231213
IS  - 1097-4652 (Electronic)
IS  - 0021-9541 (Linking)
VI  - 235
IP  - 2
DP  - 2020 Feb
TI  - A loop involving NRF2, miR-29b-1-5p and AKT, regulates cell fate of MDA-MB-231 
      triple-negative breast cancer cells.
PG  - 629-637
LID - 10.1002/jcp.29062 [doi]
AB  - The present study shows that nuclear factor erythroid 2-related factor 2 (NRF2) 
      and miR-29b-1-5p are two opposite forces which could regulate the fate of 
      MDA-MB-231 cells, the most studied triple-negative breast cancer (TNBC) cell 
      line. We show that NRF2 activation stimulates cell growth and markedly reduces 
      reactive oxygen species (ROS) generation, whereas miR-29b-1-5p overexpression 
      increases ROS generation and reduces cell proliferation. Moreover, NRF2 
      downregulates miR-29b-1-5p expression, whereas miR-29b-1-5p overexpression 
      decreases p-AKT and p-NRF2. Furthermore, miR-29b-1-5p overexpression induces both 
      inhibition of DNA N-methyltransferases (DNMT1, DNMT3A, and DNMT3B) expression and 
      re-expression of HIN1, RASSF1A and CCND2. Conversely, NRF2 activation induces 
      opposite effects. We also show that parthenolide, a naturally occurring small 
      molecule, induces the expression of miR-29b-1-5p which could suppress NRF2 
      activation via AKT inhibition. Overall, this study uncovers a novel 
      NRF2/miR-29b-1-5p/AKT regulatory loop that can regulate the fate (life/death) of 
      MDA-MB-231 cells and suggests this loop as therapeutic target for TNBC.
CI  - (c) 2019 Wiley Periodicals, Inc.
FAU - De Blasio, Anna
AU  - De Blasio A
AUID- ORCID: 0000-0003-2208-0366
AD  - Department of Biological, Chemical and Pharmaceutical Sciences and Technologies 
      (STEBICEF), Laboratory of Biochemistry (Polyclinic), University of Palermo, 
      Palermo, Italy.
FAU - Di Fiore, Riccardo
AU  - Di Fiore R
AUID- ORCID: 0000-0003-4905-6948
AD  - Department of Biological, Chemical and Pharmaceutical Sciences and Technologies 
      (STEBICEF), Laboratory of Biochemistry (Polyclinic), University of Palermo, 
      Palermo, Italy.
AD  - Sbarro Institute for Cancer Research and Molecular Medicine, Center for 
      Biotechnology, College of Science and Technology, Temple University, 
      Philadelphia, Pennsylvania.
FAU - Pratelli, Giovanni
AU  - Pratelli G
AD  - Department of Biological, Chemical and Pharmaceutical Sciences and Technologies 
      (STEBICEF), Laboratory of Biochemistry (Polyclinic), University of Palermo, 
      Palermo, Italy.
FAU - Drago-Ferrante, Rosa
AU  - Drago-Ferrante R
AD  - Department of Biological, Chemical and Pharmaceutical Sciences and Technologies 
      (STEBICEF), Laboratory of Biochemistry (Polyclinic), University of Palermo, 
      Palermo, Italy.
FAU - Saliba, Christian
AU  - Saliba C
AD  - Centre for Molecular Medicine and Biobanking, University of Malta, Msida, Malta.
FAU - Baldacchino, Shawn
AU  - Baldacchino S
AD  - Department of Pathology, Faculty of Medicine and Surgery, University of Malta, 
      Msida, Malta.
FAU - Grech, Godfrey
AU  - Grech G
AD  - Department of Pathology, Faculty of Medicine and Surgery, University of Malta, 
      Msida, Malta.
FAU - Scerri, Christian
AU  - Scerri C
AD  - Department of Physiology and Biochemistry, Faculty of Medicine and Surgery, 
      University of Malta, Msida, Malta.
FAU - Vento, Renza
AU  - Vento R
AUID- ORCID: 0000-0002-8308-4830
AD  - Sbarro Institute for Cancer Research and Molecular Medicine, Center for 
      Biotechnology, College of Science and Technology, Temple University, 
      Philadelphia, Pennsylvania.
FAU - Tesoriere, Giovanni
AU  - Tesoriere G
AD  - Sbarro Institute for Cancer Research and Molecular Medicine, Center for 
      Biotechnology, College of Science and Technology, Temple University, 
      Philadelphia, Pennsylvania.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20190710
PL  - United States
TA  - J Cell Physiol
JT  - Journal of cellular physiology
JID - 0050222
RN  - 0 (CCND2 protein, human)
RN  - 0 (Cyclin D2)
RN  - 0 (DNMT3A protein, human)
RN  - 0 (MIRN29a microRNA, human)
RN  - 0 (MicroRNAs)
RN  - 0 (NF-E2-Related Factor 2)
RN  - 0 (NFE2L2 protein, human)
RN  - 0 (RASSF1 protein, human)
RN  - 0 (Reactive Oxygen Species)
RN  - 0 (Sesquiterpenes)
RN  - 0 (Tumor Suppressor Proteins)
RN  - 2RDB26I5ZB (parthenolide)
RN  - EC 2.1.1.37 (DNA (Cytosine-5-)-Methyltransferase 1)
RN  - EC 2.1.1.37 (DNA (Cytosine-5-)-Methyltransferases)
RN  - EC 2.1.1.37 (DNA Methyltransferase 3A)
RN  - EC 2.1.1.37 (DNMT1 protein, human)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
SB  - IM
MH  - Cell Line, Tumor
MH  - Cell Proliferation/genetics
MH  - Cyclin D2/metabolism
MH  - DNA (Cytosine-5-)-Methyltransferase 1/metabolism
MH  - DNA (Cytosine-5-)-Methyltransferases/metabolism
MH  - DNA Methylation/genetics
MH  - DNA Methyltransferase 3A
MH  - Female
MH  - Gene Expression Regulation, Neoplastic/genetics
MH  - Humans
MH  - MicroRNAs/*genetics
MH  - NF-E2-Related Factor 2/*genetics
MH  - Proto-Oncogene Proteins c-akt/*genetics
MH  - Reactive Oxygen Species/metabolism
MH  - Sesquiterpenes/pharmacology
MH  - Signal Transduction/genetics
MH  - Triple Negative Breast Neoplasms/drug therapy/*genetics/pathology
MH  - Tumor Suppressor Proteins/metabolism
MH  - DNA Methyltransferase 3B
OTO - NOTNLM
OT  - AKT
OT  - DNMTs
OT  - NRF2
OT  - miR-29b-1-5p
OT  - parthenolide
OT  - tumor suppressor genes
EDAT- 2019/07/18 06:00
MHDA- 2020/10/21 06:00
CRDT- 2019/07/18 06:00
PHST- 2019/04/26 00:00 [received]
PHST- 2019/06/20 00:00 [accepted]
PHST- 2019/07/18 06:00 [pubmed]
PHST- 2020/10/21 06:00 [medline]
PHST- 2019/07/18 06:00 [entrez]
AID - 10.1002/jcp.29062 [doi]
PST - ppublish
SO  - J Cell Physiol. 2020 Feb;235(2):629-637. doi: 10.1002/jcp.29062. Epub 2019 Jul 
      10.